FY2026 EPS Estimates for MREO Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has increased its FY2026 earnings per share estimate for Mereo BioPharma Group from ($0.08) to ($0.07), while the consensus estimate is ($0.03) per share.
• Mereo BioPharma reported a quarterly loss of ($0.02) per share, missing analyst expectations, with actual revenue of only $0.50 million against estimates of $7.80 million.
• Despite mixed ratings from analysts, Mereo BioPharma has received a "buy" rating from Needham & Company with a target price of $5.00, although Wall Street Zen has downgraded it to a "sell."

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2026 EPS estimates for shares of Mereo BioPharma Group in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will earn ($0.07) per share for the year, up from their prior forecast of ($0.08). The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Mereo BioPharma Group from a "sell" rating to a "hold" rating in a research report on Saturday. Needham & Company LLC set a $5.00 target price on shares of Mereo BioPharma Group and gave the stock a "buy" rating in a research report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $7.20.

Mereo BioPharma Group Price Performance

Shares of NASDAQ:MREO traded down $0.01 during trading on Friday, reaching $1.63. 986,136 shares of the company's stock traded hands, compared to its average volume of 1,748,036. Mereo BioPharma Group has a 12 month low of $1.47 and a 12 month high of $5.02. The company has a 50 day moving average of $2.16 and a 200-day moving average of $2.35. The stock has a market capitalization of $259.17 million, a P/E ratio of -23.29 and a beta of 0.47.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $7.80 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MREO. XTX Topco Ltd bought a new position in shares of Mereo BioPharma Group in the fourth quarter valued at approximately $133,000. Walleye Capital LLC bought a new position in shares of Mereo BioPharma Group in the fourth quarter valued at approximately $454,000. Jump Financial LLC bought a new position in shares of Mereo BioPharma Group in the fourth quarter valued at approximately $39,000. Rock Springs Capital Management LP boosted its holdings in shares of Mereo BioPharma Group by 0.7% in the fourth quarter. Rock Springs Capital Management LP now owns 9,599,170 shares of the company's stock valued at $33,597,000 after acquiring an additional 65,000 shares in the last quarter. Finally, Virtus ETF Advisers LLC bought a new position in shares of Mereo BioPharma Group in the fourth quarter valued at approximately $67,000. 62.83% of the stock is currently owned by institutional investors.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.